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The discovery of RNA guided endonucleases has emerged as one of the most important tools for gene
edition and biotechnology. The selectivity and simplicity of the CRISPR/Cas9 strategy allows the
straightforward targeting and editing of particular loci in the cell genome without the requirement of
protein engineering. However, the transfection of plasmids encoding the Cas9 and the guide RNA could
lead to undesired permanent recombination and immunogenic responses. Therefore, the direct delivery
of transient Cas9 ribonucleoprotein constitutes an advantageous strategy for gene edition and other
potential therapeutic applications of the CRISPR/Cas9 system. The covalent fusion of Cas9 with
penetrating peptides requires multiple incubation steps with the target cells to achieve efficient levels of
gene edition. These and other recent reports suggested that covalent conjugation of the anionic Cas9
ribonucleoprotein to cationic peptides would be associated with a hindered nuclease activity due to
undesired electrostatic interactions. We here report a supramolecular strategy for the direct delivery of
Cas9 by an amphiphilic penetrating peptide that was prepared by a hydrazone bond formation between
a cationic peptide scaffold and a hydrophobic aldehyde tail. The peptide/protein non-covalent
nanoparticles performed with similar efficiency and less toxicity than one of the best methods described
to date. To the best of our knowledge this report constitutes the first supramolecular strategy for the
direct delivery of Cas9 using a penetrating peptide vehicle. The results reported here confirmed that
peptide amphiphilic vectors can deliver Cas9 in a single incubation step, with good efficiency and low
toxicity. This work will encourage the search and development of conceptually new synthetic systems
for transitory endonucleases direct delivery.1 Introduction
Since the clustered regularly interspaced short palindromic
repeats (CRISPR) were discovered and assigned to a bacterial
adaptive immune system,1–3 the excitement of the scientic
community towards the CRISPR technology has grown beyond
any expectation.4 The potential of editing the genome using
nucleases and in particular by RNA-guided endonucleases
(RGEN) of bacterial origin has emerged as one of the most
promising strategies for genetic engineering and gene therapy.5
The prospective applications of this technology in mammalian
cells6,7 has opened an exciting and ever growing eld, not only
as an easy-to-program nuclease for genome edition, but also as
a biotechnological tool that can be used as a regulator of the
gene expression, an epigenetic modulator, or as an imaging
agent.8 The most popular RGEN so far is Streptococcus pyogenes
Cas9 (SpCas9) that belongs to the type II CRISPR system.1
However, similar proteins from different bacterial speciesica Biolóxica e Materiais Moleculares
gánica, Universidade de Santiago de
Spain. E-mail: javier.montenegro@usc.es
tion (ESI) available. See DOI:
hemistry 2017(Staphylococcus aureus, Neisseria meningitidis, Campylobacter
jejuni)9–11 and endonucleases from other CRISPR systems, such
as type V CpfI12 have also been discovered and characterized.
The biggest advantage of these proteins is their mechanism of
target recognition, which is mostly based in the base pairing
between a RNA guide (gRNA) and the target sequence.13,14 This
straightforward DNA recognition mechanism of the CRISPR
system eliminates the need of engineering a new protein for
each target as required for transcription activator-like effector
nucleases (TALENs) or zinc-nger nucleases (ZFNs). Genome
edition by the CRISPR/Cas9 RNA guided system is commonly
achieved by the transfection of two, or in some cases one,
recombinant plasmids encoding the Cas9 protein and the guide
RNA sequences.7
However, the transfection of these plasmids might lead to
permanent DNA recombination and persistent expression of the
endonucleases, a situation that enhances potential off target
effects and immunogenic responses.15–17 Therefore, the direct
delivery of the Cas9 ribonucleoprotein (RNP) would be benecial
as it functions as a transitory effector that could be subsequently
degraded. The SpCas9 is a relatively large protein (1400 aa,
160 kDa) and thus the direct delivery of this macromolecule
inside cells is a challenging task.18 The size of SpCas9 alsoChem. Sci., 2017, 8, 7923–7931 | 7923

































































































View Article Onlineconstitutes an important limitation for its expression by plasmid
transfection or DNA delivery, as the SpCas9 gene is almost at the
loading capacity limit of the viral vectors.18–20 Therefore, there is
a growing interest in the direct delivery of the Cas9 ribonucleo-
protein (RNP) inside cells, as it enables the transient accumula-
tion of the protein in the nucleus, avoiding the aforementioned
problems of plasmid integration, prolonged residual activity and
immune responses.17
The recent search for new methods to deliver the Cas9 ribo-
nucleoprotein into the cytosol of cells has lead to different
strategies including electroporation17 or induced osmocytic
transduction (iTOP).21 The arguably most interesting complexa-
tion with non-viral carriers has been recently explored and pio-
neering protocols have been reported.22–26 The ability of
Lipofectamine 2000 to deliver this slightly negatively charged
ribonucleoprotein with good efficiency has been recently re-
ported.23 Similar methods based on bioreducible lipids24 or new
lipid formulations25 have also been developed. Other approaches
such as the inclusion of the RNP into nanoclews of DNA,27 or gold
nanoparticles26 have also been explored in the last years.
However, some of these strategies required Cas9 engineering
with negatively charged tags for the complexation with the
cationic nanocarriers.26 Cell-penetrating peptides (CPP) have
recently been fused to the Cas9 and conrmed to deliver the
nuclease in living cells.28 However, this strategy involved the
covalent fusion of the CPP to the protein and required repeated
series of incubations of the fused protein with the cells to achieve
satisfactory levels of edition.22,29 Some of these initial observa-
tions led to the idea that the application of some cationic carriers
for Cas9 direct delivery would be hindered by the potential
problems of the electrostatically bound complex of Cas9 to target
the loci and perform its nuclease activity.23 Importantly, to the
best of our knowledge, no report has yet described a supramo-
lecular strategy for the cell penetrating peptide mediated direct
delivery of the SpCas9 ribonucleoprotein.
2 Results
2.1. Design and initial screening
Recently, the amphiphilic modulation of cationic peptides by
hydrazone bond formation with hydrophobic pendants has
emerged as a conceptually new strategy to screen for the delivery
of nucleic acids.30–34 The reactive peptide reported in this study
presents a hydrophobic and a cationic domain with two parallel
reactive hydrazides placed at the amphiphilic interface (Fig. 1A).32
Although the helicity of the parent peptide (P) was low (around
15% in PBS buffer), the conjugation with the hydrophobic tails
increased the helical character of the resulting hydrazone
amphiphile (up to 35%).32 The hydrazone formation reaction is
carried out in mild and fully biocompatible conditions (i.e.
DMSO/H2O or DMSO) and the resulting peptide amphiphiles can
be directly complexed with the bioactive cargo and the cells
without any special requirement or further purication
(Fig. 1A).32 The hydrazone formation reactions were carried out in
the presence of an excess of aldehyde (6 equiv. per tail) to
maximize the presence of the di-hydrazone amphiphilic peptide.
However, control experiments showed that pure aldehyde tails7924 | Chem. Sci., 2017, 8, 7923–7931were unable to deliver the protein (Fig. S1B†). The synthesis, the
physicochemical characterization and the plasmid transfection
capabilities of this peptide (P) have recently been reported.32 In
order to validate the potential direct delivery of the Cas9 ribo-
nucleoprotein, we performed a preliminary screening by reacting
the parent peptide (P) with a wide variety of aldehyde tails (Tn).
The corresponding peptide amphiphiles (PTn) were combined
with a RNP designed to knock-out the gene encoding for the
enhanced green uorescent protein (EGFP). Thus, we incubated
an EGFP-expressingHeLa cell line with the peptide/Cas9 complex
with RNP against EGFP and, three days later, non-uorescent
cells were counted by ow cytometry (Fig. 1B). The simplicity of
the protocol allowed a quick optimization of the delivery condi-
tions such as protein/peptide ratio (Fig. S1A†).32,34 In this initial
screening, the aldehyde tails that showed gene edition activity
were octanal (T11), 10-undecenal (T15), both isomers of phytal (T17
and T18), cis-11-hexadecenal (T23), oleic aldehyde (T24) and lino-
leic aldehyde (T26). From these hydrophobic aldehydes we found
oleic aldehyde as the best hit for the delivery of the Cas9 RNP
against EGFP. Therefore, we decided to further conrm and
quantify the potential of this methodology with this particular di-
hydrazone oleic aldehyde bound peptide (PT24).2.2. Characterization of Cas9 delivery and gene edition by
PT24
The potential of PT24 for ribonucleoprotein delivery and gene
edition was fully characterized and compared with Lipofectamine
2000 by a T7-E1 endonuclease assay (Fig. 2).23 To validate the
assay, we conrmed that the maximum edition efficiency of our
control experiments with Lipofectamine 2000 were in good
agreement with the reported values.24,26 A rst dose–response
experiment was carried out by xing concentrations of peptide
and lipofectamine vectors34 that were combined with increasing
amounts of RNP (Fig. 2A). In the RNP dose–response experiments,
the efficiencies of both carriers were comparable, although Lip-
ofectamine was slightly more efficient when incubated with the
highest concentration of Cas9 tested in our experiment (Fig. 2A, in
red). However, PT24 slightly outperformed the lipidic vector at
lower concentrations of the Cas9 protein (Fig. 2A).
Delivery experiments in the presence of serum showed certain
degree of edition reduction but the hydrazone-bound peptide
and Lipofectamine efficiencies were similar (Fig. 2B and S2†). To
investigate the versatility of this peptide carrier we performed
gene editing in different cell lines and we could conrm the
peptide mediated delivery of Cas9 in different cell lines, such as
the human lung epithelial A549 and the chicken broblast DF1
cell lines (Fig. 2C and S3†). Importantly, at the concentrations of
Lipofectamine 2000 and PT24 required to achieve similar levels of
edition,34 the peptide carrier showed an improved level of cell
viability than that of the Lipofectamine as shown by the MTT
assay (Fig. 2E). Internalization studies with a TAMRA-labelled
peptide (TmPT24) in the presence of endocytic inhibitors
(Fig. 2D) were performed to investigate the uptake mechanism of
the complexes in HeLa cells (see ESI†).35,36 The almost complete
uptake inhibition at 4 C or in the presence of dynasore (an
inhibitor of dynamin-dependent endocytosis) conrmed that theThis journal is © The Royal Society of Chemistry 2017
Fig. 1 Scheme and screening. (A) Schematic representation of the amphiphilic peptide (arginine residues in blue, leucines in orange) and the
reactive hydrazides (shown in red). Reaction with a hydrophobic aldehyde affords the amphiphilic structure that can be incubated with Cas9
ribonucleoprotein to generate nanoparticles that can cross the membrane and deliver the active Cas9 into the cell. The structure of the lateral
side chain of the artificial amino acid (Hy) is shown in the dotted box. (B) Heat map for the preliminary screening with different aldehyde tails.
HeLa-EGFP cells were incubated with ribonucleoprotein with a gRNA targeting EGFP, and after 3 days, EGFP negative cells were quantified by
flow cytometry. The percentages of edition are represented by different shades of green. (All data was obtained after triplicate transfection
experiments.)

































































































View Article Onlineuptake of the peptide/protein complexes was an energy depen-
dent endocytic process (Fig. 2D). The inhibitors of caveolin/lipid-
ra mediated endocytosis (MbCD) or clathrin-mediated endocy-
tosis (CPZ) had little to no effect on the uptake level. EIPA, a quite
specic inhibitor of macropinocytosis,36 almost eliminated the
peptide uptake, suggesting that the complexes were mostly taken
up by macropinocytosis. Inhibition of the uptake in the presence
of heparin suggested an initial electrostatic interaction of the
peptide with the negatively charged glycosaminoglycans of the
cells (Fig. 2D).2.3. Peptide/protein nanoparticle characterization
To conrm the formation of stable peptide/protein complexes,
we carried out a gel retardation assay using a guide RNA labelled
with the uorescent probe ATTO550 (Fig. 3A). In this assay, we
followed the band of the uorescent gRNA alone or in the
presence of Cas9 and increasing concentrations of the cationicThis journal is © The Royal Society of Chemistry 2017peptide (Fig. 3A). The electrophoresis conrmed the complex-
ation of the RNP at the peptide concentrations required for
efficient edition (Fig. 3A). Dynamic Light Scattering (DLS) of the
peptide and the peptide/protein complexes, in buffer at physi-
ological pH (see ESI† for details, Fig. S5†), showed the presence
of nanoparticles of around 270 nm (Fig. 3B). The peptide/
protein complex showed a slightly lower diameter than the
pure peptide (270 nm vs. 300 nm), an observation that could be
related to the condensation of the particles due to the interac-
tion between the cationic peptide and the anionic ribonucleo-
protein (Fig. S5†). The zeta potential of these suspensions
revealed a positively charged nanoparticle surface of 10.4  1.8
mVs for the peptide amphiphile that was reduced to 4.2  0.5
mVs for the PT24/Cas9 RNP complex. We next studied in detail
these nanoparticles by Transmission Electron Microscopy
(TEM) (Fig. 3C–H). The TEM micrographs of pure peptide and
PT24/Cas9 RNP complexes revealed the presence ofChem. Sci., 2017, 8, 7923–7931 | 7925
Fig. 2 Quantification of the gene edition. (A) Dose response experiment. HeLa cells were treated with different amounts of RNP (indicated over
the lanes, nM) targeting the HPRT1 gene using PT24 at a ratio RNP : amphiphile of 1 : 62.5. A T7-E1 assay was performed 48 h later to quantify the
indel efficiency. (B) Cleavage efficiency in the presence of serum (160 nM RNP targeting HPRT1 in the presence of 5% serum, see Fig. S2† for the
original gel). Bar chart shows average and standard deviation of 3 replicates. (C) T7-E1 assay of human lung cancer A549 cells treated with RNP
against HPRT1 or chicken fibroblast DF-1 EGFP cells treated with RNP against EGFP using PT24 (see also Fig. S3†). (D) Uptake mechanism
following fluorescence of TmPT24 (Tm stands for TAMRA fluorophore). HeLa cells were incubated with the complexes in the presence of
different inhibitors of endocytosis and the uptake was quantified by flow cytometry. (E) MTT viability assay. HeLa cells were treated with different
amounts of RNP using Lipofectamine 2000 or PT24 at a fixed ratio in the presence of 5% serum. Two days later, viability was measured with a MTT
assay. Values are expressed as a percentage of the untreated cells control. Concentration 1 of complexes corresponds to 10 mM PT24/160 nM
RNP or 10 mg mL1 Lipofectamine 2000/160 nM RNP. In (A), (B) and (C) the cleavage efficiency (%) is indicated below each lane, peptide (blue),
Lipofectamine 2000 (red).

































































































View Article Onlinenanostructures in the same size range as obtained by DLS
(Fig. 3C–H). However, the average size obtained by TEM size (206
 24 nm and 127  37 nm for PT24 or PT24/Cas9 RNP particles
respectively as average diameter, see ESI†) was slightly lower than
the average size of the DLS (Fig. S5†). This observation could be
related with the peptide/protein condensation aer drying on top
of the microscopy grid and/or to the higher hydrodynamic radius
of the solvated particles in the aqueous environment. The slight
reduction of the particle diameter for the PT24/Cas9 RNP
complexes compared to pure peptide, which was previously
observed by DLS, could also be conrmed by electronmicroscopy
(Fig. 3D and E). These nanostructures showed a denser core and
a thinner external layer (Fig. 3C–H). In some particular cases, we
could observe morphological variants of these nanoparticles
showing intriguing dendritic and asymmetrical structures
(Fig. 3F and G). To further investigate these particles, the peptide/
protein complexes were prepared in an agarose solution and aer
gelation slices of the material were cut and observed under7926 | Chem. Sci., 2017, 8, 7923–7931transmission electron microscopy (Fig. 3H and S6†). These
pictures showed mostly spherical particles with a dense core
(150 nm) and lighter external surfaces. The total size for the gel-
immobilized particles was within the same previously observed
size range of around 230 nm in diameter (Fig. 3H). To conrm
the presence and the particular position of the ribonucleoprotein
in these nanoaggregates, we exploited an oligohistidine tag
present in the recombinant Cas9 nuclease. Thus, the PT24/
Cas9Histidine complexes were further incubated with small gold
nanoparticles (5 nm) coordinated to a nickel(II) cation (Ni-NTA
Nanogold), deposited on top of microscopy grids and observed
under scanning transmission electron microscopy (STEM, see
ESI† for details). Nanoparticles with denser cores were again
observed in the STEM mode. The interaction of the divalent
nickel with the protein histidine tag allowed the visualization of
the high contrast smaller gold nanoparticles attached to the
peptide/protein nanostructures (Fig. 3I–K). The corresponding
energy-dispersive X-ray microanalysis unambiguously conrmedThis journal is © The Royal Society of Chemistry 2017
Fig. 3 Nanoparticle characterization. (A) Agarose gel retardation electrophoresis of the gRNA-ATTO550 in the absence and presence of Cas9 and
PT24 at neutral pH (7). (B) Correlation curve and DLS diameter of PT24/Cas9 RNP complex at neutral pH (7). (C) Transmission electronmicrograph
of amphiphile (PT24) nanoparticles prepared in DMEM. (D, E) Detailed transmission electron micrographs of PT24 alone (D) and of the PT24/Cas9
RNP complex (E) in DMEM. (F, G) Detailed transmission electron micrograph of a morphologic variant of the amphiphile (PT24) nanoparticles. (H)
Transmission electronmicrographs of PT24/Cas9 RNP complex nanoparticles embedded in agarose gels. The internal core diameter (in yellow) is
around 145 nm and total particle size is around 230 nm. (I, J) Scanning transmission electron micrographs (STEM) of PT24/Cas9 RNP complexes
and co-incubated with Nanogold (5 nm gold nanoparticles functionalised with Ni-NTA for Cas9 histidine tagged identification). (K) STEM detail of
one of the PT24/Cas9 RNP particles (L) energy-dispersive X-ray microanalysis depicting the gold distribution related to (K). (M, N) CLSM images of
the RNP bound to a fluorescent gRNA in the presence (N) or absence (M) of 10 mM PT24. Scale bars represent 100 nm (C–J), 50 nm (K, L) and 10
mm (M, N).
This journal is © The Royal Society of Chemistry 2017 Chem. Sci., 2017, 8, 7923–7931 | 7927



































































































































































































View Article Onlinethe presence of the gold metal distributed at different positions
of the nano-aggregates (Fig. 3L). The incorporation of the RNP to
the peptide particles was additionally conrmed by uorescence
using the RNP with the guide RNA labelled with ATTO550
(Fig. 3M, N and S8†). As expected, the addition of the amphiphile
triggered the appearance of uorescent pixels in the red channel
of the confocal uorescent microscopy images (Fig. 3N).2.4. Endosomal disruption and cytosolic cargo release
As previously conrmed by inhibition experiments (Fig. 2D), the
cellular uptake of the PT24/Cas9 RNP complex was energy
dependent (>90%) and mostly assigned to a macropinocyticFig. 4 Lysosomal escape. (A) Lysosomal staining. HeLa cells were incubat
(green). (B) Quantitation of lysosomal fluorescence by flow cytometry. H
50 nM of LysoTracker. Fluorescence was normalized to untreated cells.
mM) and RNP (80 nM). (C) Glucocorticoid induced GFP translocation assa
show mostly cytosolic fluorescence. Upon incubation with a dexametha
translocation of the GR is triggered. (D) Translocation ratio (nuclear/cyto
(Cont), cells incubated with 1 mM dexamethasone (Dex) or with 10 mM
pinocytosis inhibitor EIPA. Error bars indicate SE. Statistical analysis (two-
between PT24 and EIPA (p-value < 0.001).
7928 | Chem. Sci., 2017, 8, 7923–7931mechanism. However, despite the fact that almost all the
complex uptake occurs through macropinocytosis, the efficient
gene edition observed for the PT24/Cas9 RNP indicates an
intrinsically required escape of the RNP from the endosome and
a subsequent cytosol release and nuclear entry to carry out the
observed nuclease activity. Therefore, to further investigate the
uptake mechanism, we acquired microscopy images of living
cells incubated with the complex TmPT24/Cas9 RNP, in where
the peptide was labelled with TAMRA uorophore (Tm) (see ESI,
Fig. S4†). These images showed the expected punctate uores-
cence together with some diffuse uorescence at the cytosol
level and near the nuclei (Fig. 4A). Intrigued by theseed (1 h) with PT24/Cas9 RNP (red) in the presence of 50 nM LysoTracker
eLa cells incubated with the same complexes as in A in the presence of
Error bars indicate SD of three measurements. In (A) and (B) peptide (5
y (GIGT assay). HeLa cells transfected with a chimeric GR–GFP protein
sone labelled peptide, if the corticoid reaches the cytosol, the nuclear
plasmic median fluorescence intensity) calculated for untreated cells
of DexPT24, in the absence (PT24) or presence (+EIPA) of the macro-
tailed t-test with Bonferroni correction) showed significant differences
This journal is © The Royal Society of Chemistry 2017

































































































View Article Onlineobservations, we studied the ability of these nanoparticle-like
structures to disrupt the lysosome and reach the cytosol.37 To
monitor the potential co-localization of the particles within the
lysosomes, HeLa cells were incubated with TmPT24/Cas9 RNP (5
mM) in the presence of a lysosomal marker (LysoTracker,
Fig. 4A).
Although we could detect a few peptide/protein complexes
within the lysosomes, we mostly noticed a substantial decrease
in the total staining of lysosomes compared to the control
experiment (Fig. 4A). This reduction in the intensity of labelled
lysosomes was conrmed and quantied by ow cytometry
(Fig. 4B). Additionally, control experiments with the non-
uorescent particles (PT24/Cas9 RNP) did also reduce the
number of stained lysosomes (Fig. S7†). Further control exper-
iments with Lipofectamine 2000 showed membrane-bound
aggregates and a much lower degree of lysosomal disruption
(Fig. S7†). Taken together, all these observations supported
a potential endosomal disruption mediated by the peptide/
protein nanostructures.
To further investigate this phenomena and to unambigu-
ously demonstrate the endosomal escape of the PT24/Cas9 RNP
complex, we implemented a glucocorticoid receptor (GR)
nuclear translocation assay.38 In this experiment, cells are
transfected with a plasmid that encodes for the expression of
a chimeric GR–GFP protein that is conned at the cell cytosol
level (Fig. 4C). Upon binding to the ligand of the protein
(dexamethasone), the chimeric receptor undergoes specic
structural changes that trigger its translocation to the cell
nucleus. Thus, we synthesized the peptide DexPT24, in which
Dex stands for a dexamethasone molecule bound to the peptide
N-terminus (Figs. S7 and S9†). Incubation of the GR–GFP
transfected cells with the DexPT24 peptide showed a substantial
level of nuclear translocation indicating that the peptide was
able to reach the cytosol (Fig. 4D). However, when the experi-
ment was repeated in the presence of the macropinocytosis
inhibitor (EIPA), the nuclear translocation effect was strongly
reduced (Fig. 4D).39 Therefore, if inhibition of macropinocytosis
blocks the presence of cytosolic peptide, we can conclude that
the peptide that reached the cytosol in the absence of the
inhibitor was unmistakably escaping from that particular
endocytic route (Fig. 4D).38,39
3 Discussion
As new applications of Cas9 emerge, there is a growing necessity
for the development of new methods for the safe and efficient
delivery of the Cas9 ribonucleoprotein inside living cells.18
Despite having shown great efficiency for the transport of other
functional proteins,40,41 cell-penetrating peptides have not been
described in the supramolecular delivery of the Cas9 ribonu-
cleoprotein. The report by Ramakrishna et al. required the
fusion of the cationic polyarginine to the C-terminal Cys intro-
duced in the SpCas9 sequence.22,29 However, this fused protein
required several rounds of incubations with the cells to achieve
good edition efficiency. The generation of SpCas9 proteins
fused to NrTP or Tat peptides has been proposed as a promising
alternative for the use of cell-penetrating peptides in RNPThis journal is © The Royal Society of Chemistry 2017delivery,28 but so far there is no published data of their effi-
ciency. These and other observations related with the low
activity of the Cas9 fused to cationic proteins or peptides led to
the idea that the cationic component might hinder Cas9
complexation with the gRNA or directly interfere with Cas9
nuclease activity in a particular genome loci.23 In this work we
develop the amphiphilic modulation of a penetrating peptide by
hydrazone bond formation,32 for the efficient supramolecular
non covalent complexation and straightforward delivery of Cas9
inside living cells.
In this study, a pro-helical cationic peptide with two hydra-
zide reactive moieties was reacted with hydrophobic aldehydes
to afford the corresponding peptide amphiphiles. The hydra-
zone connection between the peptide scaffold and the hydro-
phobic tails could be considered a covalent (molecular) bond.
However, the strategy is supramolecular in essence as it involves
the electrostatic non-covalent interaction of the cationic peptide
and the anionic proteins without the requirement of any cova-
lent fusion between peptide and protein. The strategy allows for
the fast biocompatible generation, without the requirement of
isolation or any further purication, of a library of cationic
amphiphiles for the screening of RNP delivery (Fig. 1). Fluo-
rescence knock-out experiments in HeLa-EGFP cells allowed the
quick identication of the best hydrophobic tails for the
delivery of the Cas9 ribonucleoprotein (Fig. 1B). As previously
observed for hydrazone modulated peptides32 and dendrons,30
the oleic aldehyde was the leading hit of these series (Fig. 1B).
However, we found new hydrophobic tails (i.e. phytal, T17) that
did not work for siRNA or plasmid transfection.30,32 On the other
hand, some of best aldehydes for nucleotide delivery (i.e.,
dodecanal, T16)30,32 showed little or total lack of activity.
In this regard, the incorporation of different aldehydes can
lead to nanoparticles with different size and shape. These
variations might inuence the different steps of the delivery
process such as the interaction of peptide with the protein, the
membrane translocation of the complex and most importantly,
the efficiency of the cargo delivery. In any case, the results re-
ported here conrmed that hydrazone modulation is an excel-
lent strategy for the quick optimization of the delivery vehicle
depending on the macromolecular cargo employed. We unam-
biguously conrmed the Cas9 delivery and genome edition by
a T7-E1 nuclease assay (Fig. 2). The oleic aldehyde modulated
peptide PT24 seems to be more efficient than Lipofectamine
2000 when delivering small amounts of RNP. Furthermore, the
peptide/protein vehicle (PT24/Cas9 RNP) was less toxic than
Lipofectamine, as it was previously observed for plasmid
transfection.32
The organic nanoparticle-like structures observed by elec-
tronmicroscopy depicted nanoparticles (270 nm) with a dense
core and a lighter external layer (Fig. 3). Although initially
unexpected, these layered particles have been already observed
in lipid hybrid42 or peptide amphiphile nanoparticles.43,44 A gel
retardation assay conrmed the ability of these nanoparticles to
complex Cas9 RNP. STEM images of the PT24/Cas9Histidine
complex, co-incubated with Ni-NTA Nanogold 5 nm nano-
particles, conrmed the location of the Cas9 recombinant
protein within the peptide nanoaggregates. Microscopy imagesChem. Sci., 2017, 8, 7923–7931 | 7929

































































































View Article Onlineand ow cytometry quantication of the cells treated with these
nanoparticles conrmed a substantial decrease in the number
of stained cell lysosomes (Fig. 4). This observation could be
assigned to an endosomal disruption that would lead to the
escape of the complexes from the endosome and the subse-
quent cytosolic release of the cargo. The higher degree of lyso-
somal disruption of PT24 in comparison with Lipofectamine
2000, suggested substantial differences in the uptake kinetics
andmode of action of these two protein carriers (Fig. 4 and S7†).
The endosomal escape of the peptide vehicle (PT24) was nally
unambiguously conrmed by a nuclear translocation assay that
demonstrated that the peptide was able to reach the cytosol
aer a predominant macropinocytic uptake mechanism
(Fig. 4C and D).
4 Conclusions
In summary, we conrmed that the hydrazone modulation of
a penetrating peptide carrier constitutes a suitable and
straightforward approach for the efficient delivery of Cas9
inside living cells. To the best of our knowledge, this is the rst
report of a non-covalent strategy for the delivery of Cas9 with
a penetrating peptide vehicle. This methodology circumvents
any protein engineering or covalent fusion to the peptide carrier
and allows the efficient identication of a single component
formulation for gene edition with comparable efficiency and
less toxicity than one of the best recently reported methods.23
The peptide/protein supramolecular complex (PT24/Cas9 RNP)
afforded organic nanostructures that escaped the endocytic
pathway, delivered its cargo and edited the genome of different
cell lines (HeLa, A549 and DF1). Therefore, this work conrmed
the versatility of the strategy for the screening of adaptable
carriers for different cargos in different cell lines. The results
reported here will fuel the development of innovative synthetic
systems for the direct delivery of Cas9 for genome edition.
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